1st Counsel – Lifestyle
Author:
Zymeworks Inc.
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
April 20, 2026
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
April 16, 2026
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
April 9, 2026
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
April 1, 2026
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
March 30, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences
March 24, 2026
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
March 18, 2026
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
March 18, 2026